重组人血管内皮抑制素治疗恶性胸腔积液临床观察  

Recombinant vascular endostatin therapy for malignant pleural effusion

作　　者：刘海仙 谭薇[2] LIU Haixian;TAN Wei(Department of Internal Medicine,Weifang Medical University,Weifang 261053,China;Department of Respiratory,Weifang People＇s Hospital)

机构地区：[1]潍坊医学院内科学教研室,山东潍坊261053 [2]潍坊市人民医院呼吸内科

出　　处：《潍坊医学院学报》2018年第3期217-219,共3页Acta Academiae Medicinae Weifang

摘　　要：目的观察重组人血管内皮抑制素(恩度)治疗恶性胸腔积液的疗效,评价其安全性和耐受性。方法将52例患者随机分为观察组与对照组,观察组胸腔注入恩度45mg+顺铂30mg,对照组则胸腔注入顺铂30mg,评价近期疗效以及毒副反应。结果观察组客观有效率(RR)为80.77%,疾病控制率(DCR)为88.46%.对照组RR为46.15%,DCR为69.23%.观察组RR及DCR明显高于对照组,差异有统计学意义(P<0.05),两组不良反应无明显差异(P>0.05)。结论恩度胸腔灌注给药能较好地控制恶性胸水,减轻临床症状。恩度与化疗药物联合局部治疗可能具有一定的协同作用,安全性较好,不增加化疗药物的不良反应。Objective To observe the efficacy of recombinant human endostatin（Endo） in the treatment of malignant pleural effusion and to evaluate its safety and tolerability. Methods Fifty-two patients were randomly divided into the observation group and the control group. The observation group received 45 mg of cisplatin and 30 mg of cisplatin in the thoracic cavity,and the control group received 30 mg of cisplatin in the chest cavity,the short-term efficacy and side effects were evaluated. Results The effectiveness rate was higher in observation group than that in control group（80. 77% vs. 46. 15%）（P 〈0.05）. The disease control rate was higher in observation group than that in control group（80. 77% vs. 46. 15%）（P 〈0.05）. The objective and effective rate of the experimental group was higher than that of the single drug group. Conclusion The intrathoracic injection of recombinant vascular endostatin can better control the malignant chest water and relieve the clinical symptoms. There may be a synergistic effect on the combination of Recombinant vascular endostatin and chemotherapy drugs. No increase in adverse reactions to chemotherapeutic drugs.

关 键 词：非小细胞肺肿瘤 恶性胸腔积液 恩度 胸腔灌注治疗 顺铂 

分 类 号：R969.4[医药卫生—药理学]